Bal Pharma Ltd

Designation changes and NRC/SRC reconstitution

• Re-appointed Ravindra Kothari as Director liable to retirement by rotation; designated as Executive Director, effective Oct 1, 2026.
• Virupakshaya Himesh redesignated from Executive Director to Non-Executive Director, effective Oct 1, 2026.
• NRC and SRC reconstituted: Himesh added as member; Kothari ceased as member, effective Oct 1, 2026.
• Member approval obtained at the 39th AGM held Sept 24, 2026.
• Not debarred from holding directorship by SEBI or authorities.
• Shareholding: Ravindra Kothari 500 shares; Virupakshaya Himesh 28,420 shares.

AGM details

• AGM date/time: 24 September 2026, 11:30 AM; mode: VC/OAVM.
• Remote voting window: 21–23 September 2026; cut-off date: 17 September 2026.

Resolutions and outcomes

• Ordinary: Adopt audited standalone and consolidated financial statements for year ended March 31, 2026.
• Ordinary: Declare dividend of Rs 1.20 per equity share.
• Ordinary: Re-appoint Ravindra Kumar Kothari as Director (retires by rotation).
• Ordinary: Ratify remuneration payable to Cost Auditors for FY 2026-27.
• Ordinary: Renew contract with Desa Marketing International.
• Special: Change Ravindra Kothari's designation from Non-Executive to Whole-Time Director.
• Special: Change Virupakshaya Himesh's designation from Whole-Time to Non-Executive Director.

Dividend details

• Dividend amount per share: Rs 1.20 on equity shares.

Director changes

• Ravindra Kumar Kothari re-appointed as Director; designation updated to Whole-Time Director.
• Virupakshaya Himesh designation changed to Non-Executive Director.

Auditors

• Cost Auditor remuneration for FY 2026-27 ratified.

Material related party transactions

• Desa Marketing International contract renewed; value not disclosed.
• Voting by related parties deemed invalid for the resolution.

Bal Pharma Ltd — Trading Window closed from October 01,2026 upto 48 hours after the declaration of the Financial Results of the Company for the second quarter ending on September 30,2026.

AGM Details

• Held 24 Sep 2026, 11:30–11:55 IST, via Video Conferencing/OAVM.

Key Resolutions

• Ordinary: Adopt audited standalone and consolidated financial statements with boards' and auditors' reports.
• Ordinary: Declare dividend of Rs 1.20 per equity share.
• Ordinary: Re-appoint Ravindra Kumar Kothari by rotation as director.
• Special: Ratify remuneration payable to Cost Auditors for FY2026-27.
• Special: Renew contract with Desa Marketing International.
• Special: Change Ravindra Kumar Kothari from Non-Executive Director to Whole-Time Director.
• Special: Change Virupakshaya Himesh from Whole-Time Director to Non-Executive Director.

Voting Results

• 1: Results not disclosed here; will be announced on exchanges/website within two days.
• 2: Results not disclosed here; will be announced on exchanges/website within two days.
• 3: Results not disclosed here; will be announced on exchanges/website within two days.
• 4: Results not disclosed here; will be announced on exchanges/website within two days.
• 5: Results not disclosed here; will be announced on exchanges/website within two days.
• 6: Results not disclosed here; will be announced on exchanges/website within two days.
• 7: Results not disclosed here; will be announced on exchanges/website within two days.

Dividends

• Dividend per share: Rs 1.20 for FY2025-26.

Directors & KMP

• Ravindra Kumar Kothari re-appointed by rotation; designated as Whole-Time Director.
• Virupakshaya Himesh designation changed to Non-Executive Director.

Auditors

• Statutory Auditor present; unmodified opinion; no changes disclosed.

Related Party Transactions

• No material related party transactions disclosed.

Other Material Approvals

• No other material approvals reported.

Clarification on price movement

• Clarification that there is no price-sensitive or material information driving Bal Pharma's scrip movement.
• All disclosures under SEBI Listing Obligations and Disclosure Requirements 2015 have been made within the stipulated timeframe.
• As of the date, there is no event or information needing reporting to stock exchanges.
• Price volatility is market-driven and not attributable to management or company actions.
• Company will continue to comply with Listing Regulations and disclose material information when required.

Warrant preferential issue to promoter — key terms

• Board approved allotment of 10,00,000 convertible warrants to promoter Mr. Shailesh Siroya.
• Warrants issued at ₹84 each, aggregating ₹8.40 crore.
• Conversion on a one-for-one basis within 18 months from allotment date.
• Balance 75% of subscription payable before the last conversion date.
• Promoter stake post-allotment expected at 20.89% after full exercise.
• Initial ₹2.10 crore received upfront (25% of total).
• No change in paid-up capital on warrant allotment; equity shares issued on conversion.
• Warrants are electronic with lock-in as per SEBI ICDR.
• Listing of equity shares on BSE/NSE subject to approvals.
• Postal ballot approval obtained 08 Aug 2026; NSE/BSE in-principle approvals on 04 Sep 2026.

Dividend record date

• Equity shares of Rs 10; Record Date: 17 September 2026.
• Final dividend of Rs 1.20 per share for FY 2025-26.
• Payment to shareholders on or after 24 September 2026.
• Dividend is subject to AGM approval; TDS as per Income Tax Act.
• Nil or lower TDS rates available for certain residents; submit forms online.
• Credit of TDS via Form 168 after payment.

Timeline for net proceeds utilization

• 18-month window to utilize net proceeds from the convertible warrants, from allotment date.
• Subject to requisite in-principle approval from stock exchanges.
• No change in objects or manner of utilization of proceeds.
• Regulatory basis: Regulation 162 of SEBI ICDR Regulations 2018.
• Date of filing: August 25, 2026.